Courage Against Cancer
Clinical trial eligibility is determined by factors such as cancer type, stage, treatment history, overall health, and age. Trials vary in their requirements, and patients are encouraged to consult their medical team for guidance. Resources like ClinicalTrials.gov can assist in exploring available options. Always discuss participation with healthcare providers.
The future of cancer treatment lies in combination. Discover the compelling science suggesting how repurposed drugs like ivermectin and mebendazole could work synergistically with standard therapies to improve outcomes and overcome treatment resistance.
Facing limited options? This guide helps patients and caregivers navigate the difficult path of considering repurposed drugs, emphasizing safety, open communication with your oncologist, and informed decision-making.
In a landscape dominated by hype and headlines, our foundation is dedicated to a single, clear mission: moving the conversation about repurposed drugs like ivermectin and mebendazole from anecdote to evidence through rigorous, independent science.
Courage Against Cancer announces a major milestone: funding our first preclinical trial for ivermectin and mebendazole. This is the critical first step on our rigorous path to achieve FDA approval and create a new, accessible paradigm in cancer therapy.